Mahamaya Lifesciences IPO Listing at 2% premium at ₹116 Per Share

Posted by : sachet | Tue Nov 18 2025

Click and Sign Up to Get Latest Updates on Mahamaya Lifesciences Limited

Table of Contents

Mahamaya Lifesciences IPO Listing:

On the BSE platform, shares are listed at ₹116 per share, reflecting a premium of 1.75% against the issue price of 114 per share. On the other hand, on the SME platform, shares are listed at ₹116.5 per share, reflecting a premium of 2%.

Mahamaya Lifesciences IPO Subscription Status

The Mahamaya Lifesciences IPO was subscribed 1.63 times at the close of the bidding. In this subscription, qualified institutional buyers (QIBs) received 1.19 times the allocation, and non-institutional investors (NIIs) received 3.63 times the allocation. The retail quota of the issue was subscribed to 33.33%.

Mahamaya Lifesciences IPO: Check Key Details

It is a book-building issue of 2,900 crore shares. The issue is entirely a fresh issue of 9.88 crore shares. And an offer for sale of 3.48 crore shares. The IPO is expected to be listed on the BSE and NSE with a tentative listing date of 18th November 2025. The Mahamaya Lifesciences IPO is expected to take place from 11th November 2025 to 13th November 2025. The face value of Mahamaya Lifesciences IPO shares is ₹1 per share, and the IPO price is set at ₹108 to ₹114 per share.

IPO Open Date	11th November 2025
IPO Close Date	13th November 2025
IPO Allotment Date	14th November 2025
Refund Initiation	17th November 2025
Face Value	₹10 per share
Price Band	₹108 to ₹114 per share
Lot Size	1,200 Shares
Issue Size	61,78,800 shares(aggregating up to ₹70.44 Cr)
Fresh Issue	53,29,200 shares(aggregating up to ₹60.75 Cr)
Offer for sale	5,40,000 shares of ₹10(aggregating up to ₹6.16 Cr)
Issue Type	Bookbuilding IPO
Listing At	BSE and SME
Listing Date	18th November 2025

About Mahamaya Lifesciences Limited

Mahamaya Lifesciences Limited was established in 2007 and is engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts for crop & soil health management, aiming to enhance productivity in the farming community. The company specialises in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs). The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).

Experienced management team consisting of experts.
Capability to introduce vital products for Indian Agriculture.
Development of export opportunities for products.
Ability to develop brands.
Cordial relationships with suppliers of raw materials.

Mahamaya Lifesciences Limited Financials

The company’s financial analysis is essential before applying for Mahamaya Lifesciences Limited’s IPO. Refer to the table to learn about Mahamaya Lifesciences Limited’s financial information.

Year Ended	30th June 2025	31st March 2025 (in cr.)	31st March 2024 (in cr.)	31st March 2023 (in cr.)
Assets	218.87	188.35	112.07	77.88
Revenue	84.04	267.17	162.83	137.40
Profit After Tax	4.10	12.94	5.22	3.75
EBITDA	8.04	24.64	13.36	8.91
Net Worth	53.50	49.42	24.66	19.44
Reserve and Surplus	35.73	31.66	23.41	18.19
Total Borrowing	57.72	58.11	54.63	24.37

Explanation

Mahamaya Lifesciences Limited’s revenue increased by 64% from ₹162.83 crore in March 2024 to ₹267.17 crore in March 2025. Moreover, the company’s PAT increased by 148% from ₹5.22 crores to ₹12.94 crores. Investors can analyse other relevant factors and make a decision accordingly.

Mahamaya Lifesciences IPO Objectives

The primary objective of the Mahamaya Lifesciences IPO is to raise ₹2,900.00 crore. However, before applying for the IPO, it is essential to be aware of its secondary objectives. Explore them below

Purchase of Equipment for the existing Formulation plant
Funding capital expenditure towards setting up a new technical manufacturing plant
Construction of Warehouse Building and Purchase of Machinery
Funding the working capital requirement of our Company
General Corporate purposes

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!